ArticleInternational journal of cancer2013
Deletion of the RNA-editing enzyme ADAR1 causes regression of established chronic myelogenous leukemia in mice.
Article in International journal of cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- The context-dependent role of the dsRNA response in linking A-to-I editing and ADAR to normal hematopoiesis and leukemia.Frontiers in cell and developmental biology · 2026Review
- PRMT1 Promotes the Self-renewal of Leukemia Stem Cells by Regulating Protein Synthesis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- RNA Editing in Cancer Progression.Cancers · 2023Review
- Emerging role of the RNA-editing enzyme ADAR1 in stem cell fate and function.Biomarker research · 2023Review
- ADAR1 and its implications in cancer development and treatment.Trends in genetics : TIG · 2022Review
- ADAR1 RNA editing regulates endothelial cell functions via the MDA-5 RNA sensing signaling pathway.Life science alliance · 2022Article
- Epitranscriptomics in Normal and Malignant Hematopoiesis.International journal of molecular sciences · 2020Review
- Epitranscriptomics in Hematopoiesis and Hematologic Malignancies.Blood cancer discovery · 2020Review
- ADAR, the carcinogenesis mechanisms of ADAR and related clinical applications.Annals of translational medicine · 2019Review
- ADAR1 may be involved in the proliferation of acute myeloid leukemia cells via regulation of the Wnt pathway.Cancer management and research · 2019Article
- ADAR Mediated RNA Editing Modulates MicroRNA Targeting in Human Breast Cancer.Processes (Basel, Switzerland) · 2018Article
- ADAR RNA editing in human disease; more to it than meets the I.Human genetics · 2017Review
- Review
- ADAR1 Prevents Liver Injury from Inflammation and Suppresses Interferon Production in Hepatocytes.The American journal of pathology · 2015Article
- PTBP1 induces ADAR1 p110 isoform expression through IRES-like dependent translation control and influences cell proliferation in gliomas.Cellular and molecular life sciences : CMLS · 2015Article
- New Insights into the Biological Role of Mammalian ADARs; the RNA Editing Proteins.Biomolecules · 2015Review
- [Effect of ADAR1 on the development of MLL-AF9 induced murine AML].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2015Article
- An RNA editing fingerprint of cancer stem cell reprogramming.Journal of translational medicine · 2015Article
- Global regulation of alternative splicing by adenosine deaminase acting on RNA (ADAR).RNA (New York, N.Y.) · 2013Article
- Increased levels of inosine in a mouse model of inflammation.Chemical research in toxicology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Patients with chronic myelogenous leukemia (CML) respond well to tyrosine kinase inhibitors (TKIs) of the Bcr-Abl oncoprotein. However, intolerance and resistance to these agents remains a challenge, and TKIs are unable to eradicate rare leukemia-initiating cells. Leukemia treatment would benefit from a better understanding of molecular signals that are necessary for the survival of leukemia-initiating cells but dispensable for normal hematopoietic stem cells. Leukemia-initiating cells in CML can arise from myeloid progenitor cells, a population that we have reported in normal hematopoiesis to depend on the RNA-editing enzyme adenosine deaminase acting on RNA-1 (ADAR1). We now report that Bcr-Abl transformed leukemic cells were ADAR1-dependent in a conditional ADAR1 knockout mouse model. ADAR1 deletion reversed leukocytosis and splenomegaly, and preferentially depleted primitive Lin-Sca+Kit+ (LSK) leukemic cells but not LSK cells lacking the leukemic oncoprotein. ADAR1 deletion ultimately normalized the peripheral white blood count, eliminating leukemic cells as assessed by PCR. These results uncover a novel requirement for ADAR1 in myeloid leukemic cells and indicate that ADAR1 may comprise a new molecular target for CML-directed therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.